Wednesday, February 1, 2023
HomeHealthIs It Time for But One other COVID Booster? It is Difficult

Is It Time for But One other COVID Booster? It is Difficult


SOURCES: 

Peter Hotez, MD, PhD, dean, Nationwide College of Tropical Drugs, Baylor Faculty of Drugs; co-director, Heart for Vaccine Growth, Texas Youngsters’s Hospital, Houston.

Paul Offit, MD, director, Vaccine Training Heart and professor of pediatrics, Youngsters’s Hospital of Philadelphia.

Michael T. Osterholm, PhD, director, Heart for Infectious Illness Analysis and Coverage (CIDRAP), College of Minnesota, Minneapolis.

Floor Truths. Eric Topol, MD: “The bivalent vaccine booster outperforms.” 

CDC: “COVID Information Tracker: Weekly Assessment,” “Charges of Laboratory-Confirmed COVID-19 Hospitalizations by Vaccination Standing,” “Development within the Variety of COVID-19 Vaccinations within the U.S.”

FDA: “Vaccine and Associated Organic Merchandise Advisory Committee January 26 Assembly Announcement.”

The New England Journal of Drugs: “Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters,” “Antibody Response to Omicron BA.4-BA.5 Bivalent Booster,” “Neutralization in opposition to BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster,” “Bivalent Covid-19 Vaccines – A Cautionary Story.”

Nature Drugs: “Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster.”

BioRxiv: “Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variants,” “Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine.”

Kaiser Household Basis: “ How A lot Might COVID-19 Vaccines Value the U.S. After Commercialization?”

Alison Chartan, spokesperson, Novavax.

Pfizer Media Relations.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments